TTP and atypical HUS share similar signs and symptoms. Although there is an overlap in clinical presentation, TTP is a disease of severe ADAMTS13 deficiency (≤10%), while levels of ADAMTS13 >10% in the context of microangiopathy should raise clinical suspicion of atypical HUS.
Consequences of TTP and atypical HUS make rapid diagnosis and clinical intervention critical; therefore, increased availability of a diagnostic test for ADAMTS13 activity is extremely important in delineating between TTP and atypical HUS. In an effort to achieve this goal, the following centres are now providing timely (24-48 hours) turnaround of ADAMTS13 testing. Note: blood draws for ADAMTS13 activity testing should be done prior to commencing plasma-based therapy.
Total: 7 results found.
Hina Chaudhry, BSc, MLT Special Coagulation Department of Laboratory Medicine 30 Bond St Toronto, ON, M5B 1X8 Coagulation Lab: 416-864-5119 416-864-6060 ext 5123Details
Jacqueline Ongteco, MLT Charge Technologist Coagulation Laboratory University Health Network 200 Elizabeth St Toronto, ON, M5G 2C4 416-340-4800 ext 8305Details
Jane Moore, ART, BSc Research Coordinator McMaster Platelet Immunology HSC 3H42 1200 Main St W Hamilton, ON, L8S 4K1 905-525-9140 extDetails
Sheila Bouwmeester, ART Hemostasis and Thrombosis Laboratory London Health Sciences Centre 800 Commissioners Rd E, Room D1-210 London, ON, N6A 5W9 519-685-8300 ext @lhsc.on.caltig.lhsc.on.caDetails
Marvin J Fritzler, PhD, MD Mitogen Advanced Diagnostics Laboratory Faculty of Medicine, HRB431 3330 Hospital Dr NW Calgary, AB, T2N 4N1 403-220-3533Details